XDNA
Kelly CRISPR & Gene Editing Tech ETF
NAV as of
4 Week: 7.39 - 8.37
52 Week: 7.39 - 12.37
Latest Closing Price
7.42
Premium / Discount
1.72
Expense Ratio
0.78%
Investment Objective
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -25.35 | 1.98 | -12.78 |
| 1 Day | 0.14 | 0.00 | 0.00 |
| 1 Week | -1.20 | 1.66 | -0.72 |
| 1 Month | -11.98 | 5.13 | -2.33 |
| 3 Months | -15.39 | 12.15 | -1.27 |
| 6 Months | -16.35 | 20.17 | -0.81 |
| 1 Year | -36.12 | 34.13 | -1.06 |
| 2 Years | 0.00 | 0.00 | 0.00 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 25/06/2023 | 29/06/2023 | 0.0800 |
| 28/12/2022 | 04/01/2023 | 0.0433 |
| 21/12/2022 | 26/12/2022 | 0.0093 |
Portfolio Data
Total Number of Holdings: 25
Number of Bond Holdings: 0
Number of Equity Holdings: 23
Total Market Value: 2,178,969
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Beam Therapeutics Inc | 11.6279 | 10,548 | 0 | 253,363 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 11.44 |
| Large | 15.14 |
| Medium | 15.65 |
| Small | 9.52 |
| Micro | 48.01 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
17.3367
Price/Book*
2.1786
Price/Sales*
2.2702
Price/Cash Flow*
14.4345
Dividend Yield*
0.6152
Growth Measures
Long-Term Earnings
5.8097
Historical Earnings
16.2686
Sales Growth
-6.3064
Cash-Flow Growth
-5.2452
Book-Value Growth
-8.3822
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
